AbbVie Inc. Stock
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 0.000% | -1.837% | -1.434% | -1.029% | -2.037% | 31.259% | 106.593% |
| BioMarin Pharmaceutical Inc. | -0.080% | -5.167% | -0.952% | -21.805% | -1.925% | -43.279% | -23.070% |
| Johnson & Johnson | -2.170% | 1.730% | 3.043% | 41.421% | 19.752% | 45.724% | 56.107% |
| Biogen Inc. | 0.190% | -1.973% | -4.014% | 24.267% | 6.106% | -36.387% | -27.164% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.
Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.
Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.
Comments
News
The Best Dividend Stocks to Buy and Hold Forever
Dividend investing is a proven way to grow your wealth over the long run. But for the strategy to work, investors need to pick quality income stocks, those with robust underlying businesses that are
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell
There were times when investors may have worried about hanging onto AbbVie (NYSE: ABBV) stock.
A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
Dividend stocks can make for great long-term investments. They can generate a steady stream of income for your portfolio, not only padding your overall returns but also providing you with a way to